Hematologia e Hemoterapia

Role of Hematopoietic Cell Transplantation in Pediatric and Adult Hemophagocytic Lymphohistiocytosis-Remaining Unknowns and Challenges.

Hematology/oncology clinics of North America. 2025 Jun; 39(Jun):645-660. doi: 10.1016/j.hoc.2025.03.002. pii: S0889-8588(25)00027-9.

Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS).

Hematology/oncology clinics of North America. 2025 Jun; 39(Jun):617-643. doi: 10.1016/j.hoc.2025.02.005. pii: S0889-8588(25)00020-6.

Macrophage Activation Syndrome: Not Just for Rheumatologists Anymore.

Hematology/oncology clinics of North America. 2025 Jun; 39(Jun):597-615. doi: 10.1016/j.hoc.2025.02.004. pii: S0889-8588(25)00019-X.

Recognizing and Managing Secondary Hemophagocytic Lymphohistiocytosis in Adults: A Practical Clinical Guide.

Hematology/oncology clinics of North America. 2025 Jun; 39(Jun):577-596. doi: 10.1016/j.hoc.2025.02.007. pii: S0889-8588(25)00025-5.

Clinical Characteristics and Treatment of Familial Hemophagocytic Lymphohistiocytosis.

Hematology/oncology clinics of North America. 2025 Jun; 39(Jun):553-575. doi: 10.1016/j.hoc.2025.02.003. pii: S0889-8588(25)00018-8.

Genetics of Familial Hemophagocytic Lymphohistiocytosis (HLH).

Hematology/oncology clinics of North America. 2025 Jun; 39(Jun):531-551. doi: 10.1016/j.hoc.2025.02.002. pii: S0889-8588(25)00017-6.

Genomic Alterations in Langerhans Cell Histiocytosis.

Hematology/oncology clinics of North America. 2025 Jun; 39(Jun):491-511. doi: 10.1016/j.hoc.2025.02.001. pii: S0889-8588(25)00016-4.

Molecular Pathogenesis of the Histiocytic and Dendritic Cell Neoplasms.

Hematology/oncology clinics of North America. 2025 Jun; 39(Jun):471-490. doi: 10.1016/j.hoc.2025.03.001. pii: S0889-8588(25)00026-7.

Clinical Characteristics and Treatment of Histiocytic Disorders in Children.

Hematology/oncology clinics of North America. 2025 Jun; 39(Jun):513-529. doi: 10.1016/j.hoc.2025.02.006. pii: S0889-8588(25)00024-3.

Reclassification of Acute Myeloid Leukemia According to the 2022 World Health Organization Classification and the International Consensus Classification Using Open-Source Data.

Annals of laboratory medicine. 2025 Mar; 45(Mar):170-177. doi: 10.3343/alm.2024.0194. pii: .

How do I analyze the role of red blood cell transfusions on clinical outcome in anemic patients? Disentangling the effect of red blood cell transfusions from pre-operative anemia on post-operative outcome.

Transfusion. 2025 May; 65(May):814-821. doi: 10.1111/trf.18224. pii: .

Comparing the efficacy and safety of first-line treatments for chronic lymphocytic leukemia: a network meta-analysis.

Journal of the National Cancer Institute. 2025 Feb; 117(Feb):322-334. doi: 10.1093/jnci/djae245. pii: .

Classic Hodgkin lymphoma: Pathobiological features that impact emerging therapies.

Blood reviews. 2025 May; 71(May):101271. doi: 10.1016/j.blre.2025.101271. pii: S0268-960X(25)00016-5.

Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT.

Blood. 2025 May; 145(May):1987-2001. doi: 10.1182/blood.2024025131. pii: .

Aging platelets shift their hemostatic properties to inflammatory functions.

Blood. 2025 Apr; 145(Apr):1568-1582. doi: 10.1182/blood.2024024901. pii: .

Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma.

Blood. 2025 Apr; 145(Apr):1536-1552. doi: 10.1182/blood.2023022197. pii: .

Alemtuzumab for haematological malignancies.

Annals of hematology. 2025 May; 104(May):2593-2603. doi: 10.1007/s00277-025-06344-8. pii: .

Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management.

American journal of hematology. 2025 May; 100(May):860-891. doi: 10.1002/ajh.27625. pii: .

Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia.

Blood advances. 2025 Mar; 9(Mar):1392-1404. doi: 10.1182/bloodadvances.2024013304. pii: .

Clinical Outcomes and Treatment Strategies of Adult Transplant-Associated Thrombotic Microangiopathy: External Validation of Harmonizing Definitions and High-Risk Criteria.

American journal of hematology. 2025 May; 100(May):830-839. doi: 10.1002/ajh.27651. pii: .

New-onset hematologic disorders following COVID-19 vaccination: a systematic review.

Clinical and experimental vaccine research. 2025 Apr; 14(Apr):169-184. doi: 10.7774/cevr.2025.14.e20. pii: .

Immune Thrombotic Thrombocytopenic Purpura: A Review.

JAMA. 2025 May; doi: 10.1001/jama.2025.3807. pii: .

2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura.

Journal of thrombosis and haemostasis : JTH. 2025 Jun; doi: 10.1016/j.jtha.2025.06.002. pii: S1538-7836(25)00360-5.

Impact of Conditioning Intensity on Clinical Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Relapse After First Transplantation.

American journal of hematology. 2025 May; doi: 10.1002/ajh.27709. pii: .

Iron Deficiency in Adults: A Review.

JAMA. 2025 May; 333(May):1813-1823. doi: 10.1001/jama.2025.0452. pii: .

International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology.

Journal of thrombosis and haemostasis : JTH. 2024 Sep; 22(Sep):2629-2652. doi: 10.1016/j.jtha.2024.05.026. pii: S1538-7836(24)00318-0.

A British Society for Haematology guideline on the assessment and management of bleeding risk prior to invasive procedures.

British journal of haematology. 2024 May; 204(May):1697-1713. doi: 10.1111/bjh.19360. pii: .

Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline.

British journal of haematology. 2024 Jan; doi: 10.1111/bjh.19236. pii: .

Diagnosis and management of heparin-induced thrombocytopenia: Third edition.

British journal of haematology. 2024 Feb; 204(Feb):459-475. doi: 10.1111/bjh.19180. pii: .

Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies.

Transplantation and cellular therapy. 2024 Oct; 30(Oct):955-969. doi: 10.1016/j.jtct.2024.07.018. pii: S2666-6367(24)00549-9.

Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper.

British journal of haematology. 2024 Feb; doi: 10.1111/bjh.19333. pii: .

Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN. 2024 Oct; 22(Oct):563-576. doi: 10.6004/jnccn.2024.0051. pii: .

Expert consensus guidelines: Intravenous iron uses, formulations, administration, and management of reactions.

American journal of hematology. 2024 Jan; doi: 10.1002/ajh.27220. pii: .

Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage.

JAMA. 2016 Nov; 316(Nov):2025-2035. doi: 10.1001/jama.2016.9185. pii: .

2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura.

Journal of thrombosis and haemostasis : JTH. 2025 Jun; doi: 10.1016/j.jtha.2025.06.002. pii: S1538-7836(25)00360-5.

Macrophage Activation Syndrome: Not Just for Rheumatologists Anymore.

Hematology/oncology clinics of North America. 2025 Jun; 39(Jun):597-615. doi: 10.1016/j.hoc.2025.02.004. pii: S0889-8588(25)00019-X.

Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS).

Hematology/oncology clinics of North America. 2025 Jun; 39(Jun):617-643. doi: 10.1016/j.hoc.2025.02.005. pii: S0889-8588(25)00020-6.

Clinical Characteristics and Treatment of Histiocytic Disorders in Children.

Hematology/oncology clinics of North America. 2025 Jun; 39(Jun):513-529. doi: 10.1016/j.hoc.2025.02.006. pii: S0889-8588(25)00024-3.

Clinical Characteristics and Treatment of Familial Hemophagocytic Lymphohistiocytosis.

Hematology/oncology clinics of North America. 2025 Jun; 39(Jun):553-575. doi: 10.1016/j.hoc.2025.02.003. pii: S0889-8588(25)00018-8.

Recognizing and Managing Secondary Hemophagocytic Lymphohistiocytosis in Adults: A Practical Clinical Guide.

Hematology/oncology clinics of North America. 2025 Jun; 39(Jun):577-596. doi: 10.1016/j.hoc.2025.02.007. pii: S0889-8588(25)00025-5.

Genetics of Familial Hemophagocytic Lymphohistiocytosis (HLH).

Hematology/oncology clinics of North America. 2025 Jun; 39(Jun):531-551. doi: 10.1016/j.hoc.2025.02.002. pii: S0889-8588(25)00017-6.

Genomic Alterations in Langerhans Cell Histiocytosis.

Hematology/oncology clinics of North America. 2025 Jun; 39(Jun):491-511. doi: 10.1016/j.hoc.2025.02.001. pii: S0889-8588(25)00016-4.

Molecular Pathogenesis of the Histiocytic and Dendritic Cell Neoplasms.

Hematology/oncology clinics of North America. 2025 Jun; 39(Jun):471-490. doi: 10.1016/j.hoc.2025.03.001. pii: S0889-8588(25)00026-7.

Role of Hematopoietic Cell Transplantation in Pediatric and Adult Hemophagocytic Lymphohistiocytosis-Remaining Unknowns and Challenges.

Hematology/oncology clinics of North America. 2025 Jun; 39(Jun):645-660. doi: 10.1016/j.hoc.2025.03.002. pii: S0889-8588(25)00027-9.